#1 Clinical Trials Search in Europe

Neridronate Sodium

Neridronate Sodium, a bisphosphonate medication, is being studied in clinical trials as a potential treatment for osteogenesis imperfecta (OI) in children. This rare genetic disorder, also known as “brittle bone disease,” causes bones to break easily. The ongoing research aims to evaluate the effectiveness and safety of Neridronate Sodium compared to other bisphosphonates in reducing fracture rates and improving bone density in young patients with OI.

Table of Contents

What is Neridronate Sodium?

Neridronate Sodium is a medication that belongs to a class of drugs called bisphosphonates[1]. It is primarily used to treat bone disorders and is available under the brand name NERIXIA[1]. Bisphosphonates are a group of medicines that help to strengthen bones and prevent bone loss.

Medical Conditions Treated

Neridronate Sodium is used to treat various bone-related conditions, including:

  • Osteogenesis Imperfecta (OI): This is a genetic disorder characterized by fragile bones that break easily. It’s also known as “brittle bone disease”[1].
  • Osteoporosis: A condition where bones become weak and fragile, increasing the risk of fractures.
  • Paget’s disease of bone: A disorder that causes bones to grow larger and weaker than normal.
  • Bone metastases: When cancer spreads to the bones from other parts of the body.

How It Works

Neridronate Sodium works by slowing down the process of bone breakdown in your body. It helps to maintain bone density and strength by:

  • Inhibiting the activity of cells called osteoclasts, which are responsible for breaking down bone tissue.
  • Promoting the activity of osteoblasts, cells that build new bone.
  • Reducing the risk of fractures by improving bone mineral density.

Administration

Neridronate Sodium is typically administered as an intravenous (IV) infusion. This means it’s given directly into your vein through a needle or catheter[1]. The infusion is usually done in a hospital or clinic setting under the supervision of healthcare professionals.

Dosage

The dosage of Neridronate Sodium can vary depending on the condition being treated and the patient’s individual needs. Based on the available information:

  • For NERIXIA 25 mg solution for injection, the maximum daily dose is 25 mg[1].
  • For NERIXIA 100 mg concentrate for solution for infusion, the maximum daily dose is also 25 mg[1].

The treatment period can last up to 12 months, but this may vary based on your doctor’s recommendation and your body’s response to the medication.

Potential Side Effects

Like all medications, Neridronate Sodium can cause side effects, although not everyone experiences them. Some potential side effects may include:

  • Flu-like symptoms (fever, chills, body aches)
  • Nausea or vomiting
  • Bone, joint, or muscle pain
  • Headache
  • Fatigue

It’s important to discuss any side effects with your healthcare provider.

Precautions

Before starting treatment with Neridronate Sodium, inform your doctor if you:

  • Have kidney problems
  • Are pregnant or planning to become pregnant
  • Are breastfeeding
  • Have low blood calcium levels
  • Have had recent dental work or plan to have dental procedures

Comparison to Other Bisphosphonates

Neridronate Sodium is one of several bisphosphonates used to treat bone disorders. Other commonly used bisphosphonates include:

  • Pamidronate Disodium: Used to treat similar conditions as Neridronate Sodium[1].
  • Zoledronic Acid: Another bisphosphonate used for bone disorders[1].

Your doctor will determine which bisphosphonate is most appropriate for your specific condition and medical history.

Remember, this information is meant to supplement, not replace, the advice of your healthcare provider. Always consult with your doctor or pharmacist for personalized medical advice.

Aspect Details
Drug Name Neridronate Sodium
Condition Studied Osteogenesis Imperfecta (Types I, III, IV)
Age Group Children 2 to <7 years old
Administration Intravenous, once a month
Dosage 20 mg/kg
Study Duration Up to 24 months (minimum 12 months)
Primary Objective Evaluate effect on fracture rate reduction
Secondary Objectives Assess safety, bone density changes, quality of life
Comparison Versus other intravenous bisphosphonates

FAQ

  • What is Neridronate Sodium? Neridronate Sodium is a type of bisphosphonate medication. Bisphosphonates are drugs that help strengthen bones and reduce the risk of fractures in conditions like osteogenesis imperfecta.
  • How is Neridronate Sodium administered in the clinical trial? In the clinical trial, Neridronate Sodium is administered intravenously (through a vein) once a month. The dosage used in the study is 20 mg/kg.
  • What age group of children is being studied in this clinical trial? The clinical trial is studying children between 2 and 7 years of age who have been diagnosed with osteogenesis imperfecta Types I, III, or IV.
  • What are the main goals of the clinical trial involving Neridronate Sodium? The main goals are to evaluate how well Neridronate Sodium reduces fracture rates (including spine fractures), assess its safety, and compare its effectiveness to other intravenous bisphosphonates in children with osteogenesis imperfecta.
  • How long does the clinical trial last? The active-controlled period of the trial lasts up to 24 months, with a minimum duration of 12 months. After this, there is an extension period where all participants receive Neridronate Sodium for at least 12 more months.

Ongoing Clinical Trials on Neridronate Sodium

  • Study Comparing Setrusumab and Bisphosphonates for Children with Osteogenesis Imperfecta

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy The Netherlands Poland

Glossary

  • Osteogenesis Imperfecta (OI): A genetic disorder characterized by fragile bones that break easily, also known as 'brittle bone disease'.
  • Bisphosphonates: A class of drugs that help prevent bone loss and are used to treat conditions like osteoporosis and osteogenesis imperfecta.
  • Intravenous (IV): A method of administering medication directly into a vein.
  • Morphometric Vertebral Fractures: Fractures in the bones of the spine that can be detected through imaging but may not always cause noticeable symptoms.
  • Bone Mineral Density (BMD): A measurement of how much mineral matter is in your bones, used to assess bone strength.
  • DXA (Dual-energy X-ray Absorptiometry): A type of scan used to measure bone density.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body.
  • Adverse Events: Any unfavorable or unintended sign, symptom, or disease that occurs during a medical treatment or procedure.
  • Randomization: The process of randomly assigning participants to different treatment groups in a clinical trial to reduce bias.

References

  1. http://clinicaltrials.eu/trial/study-comparing-setrusumab-and-bisphosphonates-for-children-with-osteogenesis-imperfecta/